Anzhelika G Vorobyeva

List of Publications by Year in Descending Order

43 papers	404 citations	12 h-index	16 g-index
51 ext. papers	571 ext. citations	5.9 avg, IF	3.85 L-index

#	Paper	IF	Citations
43	Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules. *Biomedicines*, **2022**, 10, 1293	4.8	0
42	Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. *Pharmaceutics*, **2021**, 13,	6.4	1
41	The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy. *Pharmaceutics*, **2021**, 13,	6.4	2
40	Preclinical Evaluation of Tc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
39	Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution. *Pharmaceutics*, **2021**, 13,	6.4	2
38	Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use. *Bulletin of Siberian Medicine*, **2021**, 20, 23-30	0.4	4
37	Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody Molecules Lu-ABY-271 and Lu-ABY-027: Impact of DOTA Position on ABD Domain. *Pharmaceutics*, **2021**, 13,	6.4	2
36	Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1. *Cancers*, **2021**, 13,	6.6	3
35	Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle. *Biomaterials*, **2021**, 266, 120381	15.6	3
34	Phase I Study of Tc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer. *Journal of Nuclear Medicine*, **2021**, 62, 493-499	8.9	25
33	Comparative Evaluation of Novel Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting. *Cancers*, **2021**, 13,	6.6	6
32	Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model. *Cancers*, **2021**, 13,	6.6	4
31	Phase I trial of Tc-(HE)-G3, a DARPin-based probe for imaging of HER2 expression in breast cancer. *Journal of Nuclear Medicine*, **2021**,	8.9	9
30	HER3 PET Imaging: Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to Zr-Labeled Antibody and Antibody-Fragment-Based Tracers. *Cancers*, **2021**, 13,	6.6	2
29	Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
28	Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules. *Molecules*, **2020**, 25,	4.8	7
27	Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	4

26	On the prevention of kidney uptake of radiolabeled DARPins. *EJNMMI Research*, **2020**, 10, 7	3.6	11
25	Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. *Cancers*, **2020**, 13,	6.6	7
24	Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1. *International Journal of Biological Macromolecules*, **2020**, 145, 216-225	7.9	13
23	Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1. *Molecules*, **2020**, 25,	4.8	6
22	Investigation of a Pharmacological Approach for Reduction of Renal Uptake of Radiolabeled ADAPT Scaffold Protein. *Molecules*, **2020**, 25,	4.8	4
21	Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting. *Scientific Reports*, **2020**, 10, 20777	4.9	6
20	Preparation of Conjugates for Affibody-Based PNA-Mediated Pretargeting. *Methods in Molecular Biology*, **2020**, 2105, 283-304	1.4	3
19	Indirect Radioiodination of DARPin G3 Using N-succinimidyl--Iodobenzoate Improves the Contrast of HER2 Molecular Imaging. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	12
18	Selection of the optimal macrocyclic chelators for labeling with In and Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 140, 109-120	5.7	12
17	Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist Lu-DOTAGA-PEG -RM26. *International Journal of Cancer*, **2019**, 145, 3347-3358	7.5	14
16	Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake. *Scientific Reports*, **2019**, 9, 6779	4.9	6
15	Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting. *Biomaterials*, **2019**, 203, 73-85	15.6	13
14	Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2. *International Journal of Oncology*, **2019**, 54, 1209-1220	4.4	9
13	Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of Ga-Labeled Tracers. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	15
12	Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates. *Cancers*, **2019**, 11,	6.6	6
11	Optimal composition and position of histidine-containing tags improves biodistribution of Tc-labeled DARPin G3. *Scientific Reports*, **2019**, 9, 9405	4.9	23
10	Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts. *Scientific Reports*, **2019**, 9, 14907	4.9	9
9	Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 134, 37-48	5.7	15

8	Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties. *Molecular Pharmaceutics*, **2019**, 16, 995-1008	5.6	23
7	Influence of composition of cysteine-containing peptide-based chelators on biodistribution of Tc-labeled anti-EGFR affibody molecules. *Amino Acids*, **2018**, 50, 981-994	3.5	11
6	Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors. *Contrast Media and Molecular Imaging*, **2018**, 2018, 6930425	3.2	24
5	Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with In and Ga. *Molecular Pharmaceutics*, **2018**, 15, 2674-2683	5.6	12
4	Cyclic versus Noncyclic Chelating Scaffold for Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. *Molecular Pharmaceutics*, **2018**, 15, 175-185	5.6	24
3	Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs. *Cells*, **2018**, 7,	7.9	14
2	Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy. *Scientific Reports*, **2018**, 8, 9643	4.9	8
1	Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m. *Scientific Reports*, **2017**, 7, 14780	4.9	13